Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy

Roberta Antonia Diotti, Nicasio Mancini, Nicola Clementi, Giuseppe Sautto, Guisella Janett Moreno, Elena Criscuolo, Francesca Cappelletti, Petr Man, Eric Forest, Louise Remy, Simone Giannecchini, Massimo Clementi, Roberto Burioni

Research output: Contribution to journalArticle

Abstract

JC virus (JCPyV) has gained novel clinical importance as cause of progressive multifocal leukoencephalopathy (PML), a rare demyelinating disease recently associated to immunomodulatory drugs, such as natalizumab used in multiple sclerosis (MS) cases. Little is known about the mechanisms leading to PML, and this makes the need of PML risk stratification among natalizumab-treated patients very compelling. Clinical and laboratory-based risk-stratification markers have been proposed, one of these is represented by the JCPyV-seropositive status, which includes about 54% of MS patients. We recently proposed to investigate the possible protective role of neutralizing humoral immune response in preventing JCPyV reactivation. In this proof-of-concept study, by cloning the first human monoclonal antibody (GRE1) directed against a neutralizing epitope on JCPyV/VP1, we optimized a robust anti-JCPyV neutralization assay. This allowed us to evaluate the neutralizing activity in JCPyV-positive sera from MS patients, demonstrating the lack of correlation between the level of anti-JCPyV antibody and anti-JCPyV neutralizing activity. Relevant consequences may derive from future clinical studies induced by these findings; indeed the study of the serum anti-JCPyV neutralizing activity could allow not only a better risk stratification of the patients during natalizumab treatment, but also a better understanding of the pathophysiological mechanisms leading to PML, highlighting the contribution of peripheral versus central nervous system JCPyV reactivation. Noteworthy, the availability of GRE1 could allow the design of novel immunoprophylactic strategies during the immunomodulatory treatment.

Original languageEnglish
Pages (from-to)94-103
Number of pages10
JournalAntiviral Research
Volume108
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Progressive Multifocal Leukoencephalopathy
Neutralizing Antibodies
Organism Cloning
Epitopes
Monoclonal Antibodies
Multiple Sclerosis
JC Virus
Demyelinating Diseases
Therapeutics
Humoral Immunity
Rare Diseases
Serum
Anti-Idiotypic Antibodies
Central Nervous System
Natalizumab
Pharmaceutical Preparations

Keywords

  • JCPyV
  • Monoclonal antibody
  • Multiple sclerosis
  • Natalizumab
  • Neutralizing activity
  • Progressive multifocal leukoencephalopathy (PML)

ASJC Scopus subject areas

  • Virology
  • Pharmacology
  • Medicine(all)

Cite this

Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody : Epitope definition and implications in risk stratification of patients under natalizumab therapy. / Diotti, Roberta Antonia; Mancini, Nicasio; Clementi, Nicola; Sautto, Giuseppe; Moreno, Guisella Janett; Criscuolo, Elena; Cappelletti, Francesca; Man, Petr; Forest, Eric; Remy, Louise; Giannecchini, Simone; Clementi, Massimo; Burioni, Roberto.

In: Antiviral Research, Vol. 108, No. 1, 2014, p. 94-103.

Research output: Contribution to journalArticle

Diotti, Roberta Antonia ; Mancini, Nicasio ; Clementi, Nicola ; Sautto, Giuseppe ; Moreno, Guisella Janett ; Criscuolo, Elena ; Cappelletti, Francesca ; Man, Petr ; Forest, Eric ; Remy, Louise ; Giannecchini, Simone ; Clementi, Massimo ; Burioni, Roberto. / Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody : Epitope definition and implications in risk stratification of patients under natalizumab therapy. In: Antiviral Research. 2014 ; Vol. 108, No. 1. pp. 94-103.
@article{4199840732e24a81b9c9e0a24cba59a1,
title = "Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy",
abstract = "JC virus (JCPyV) has gained novel clinical importance as cause of progressive multifocal leukoencephalopathy (PML), a rare demyelinating disease recently associated to immunomodulatory drugs, such as natalizumab used in multiple sclerosis (MS) cases. Little is known about the mechanisms leading to PML, and this makes the need of PML risk stratification among natalizumab-treated patients very compelling. Clinical and laboratory-based risk-stratification markers have been proposed, one of these is represented by the JCPyV-seropositive status, which includes about 54{\%} of MS patients. We recently proposed to investigate the possible protective role of neutralizing humoral immune response in preventing JCPyV reactivation. In this proof-of-concept study, by cloning the first human monoclonal antibody (GRE1) directed against a neutralizing epitope on JCPyV/VP1, we optimized a robust anti-JCPyV neutralization assay. This allowed us to evaluate the neutralizing activity in JCPyV-positive sera from MS patients, demonstrating the lack of correlation between the level of anti-JCPyV antibody and anti-JCPyV neutralizing activity. Relevant consequences may derive from future clinical studies induced by these findings; indeed the study of the serum anti-JCPyV neutralizing activity could allow not only a better risk stratification of the patients during natalizumab treatment, but also a better understanding of the pathophysiological mechanisms leading to PML, highlighting the contribution of peripheral versus central nervous system JCPyV reactivation. Noteworthy, the availability of GRE1 could allow the design of novel immunoprophylactic strategies during the immunomodulatory treatment.",
keywords = "JCPyV, Monoclonal antibody, Multiple sclerosis, Natalizumab, Neutralizing activity, Progressive multifocal leukoencephalopathy (PML)",
author = "Diotti, {Roberta Antonia} and Nicasio Mancini and Nicola Clementi and Giuseppe Sautto and Moreno, {Guisella Janett} and Elena Criscuolo and Francesca Cappelletti and Petr Man and Eric Forest and Louise Remy and Simone Giannecchini and Massimo Clementi and Roberto Burioni",
year = "2014",
doi = "10.1016/j.antiviral.2014.05.017",
language = "English",
volume = "108",
pages = "94--103",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody

T2 - Epitope definition and implications in risk stratification of patients under natalizumab therapy

AU - Diotti, Roberta Antonia

AU - Mancini, Nicasio

AU - Clementi, Nicola

AU - Sautto, Giuseppe

AU - Moreno, Guisella Janett

AU - Criscuolo, Elena

AU - Cappelletti, Francesca

AU - Man, Petr

AU - Forest, Eric

AU - Remy, Louise

AU - Giannecchini, Simone

AU - Clementi, Massimo

AU - Burioni, Roberto

PY - 2014

Y1 - 2014

N2 - JC virus (JCPyV) has gained novel clinical importance as cause of progressive multifocal leukoencephalopathy (PML), a rare demyelinating disease recently associated to immunomodulatory drugs, such as natalizumab used in multiple sclerosis (MS) cases. Little is known about the mechanisms leading to PML, and this makes the need of PML risk stratification among natalizumab-treated patients very compelling. Clinical and laboratory-based risk-stratification markers have been proposed, one of these is represented by the JCPyV-seropositive status, which includes about 54% of MS patients. We recently proposed to investigate the possible protective role of neutralizing humoral immune response in preventing JCPyV reactivation. In this proof-of-concept study, by cloning the first human monoclonal antibody (GRE1) directed against a neutralizing epitope on JCPyV/VP1, we optimized a robust anti-JCPyV neutralization assay. This allowed us to evaluate the neutralizing activity in JCPyV-positive sera from MS patients, demonstrating the lack of correlation between the level of anti-JCPyV antibody and anti-JCPyV neutralizing activity. Relevant consequences may derive from future clinical studies induced by these findings; indeed the study of the serum anti-JCPyV neutralizing activity could allow not only a better risk stratification of the patients during natalizumab treatment, but also a better understanding of the pathophysiological mechanisms leading to PML, highlighting the contribution of peripheral versus central nervous system JCPyV reactivation. Noteworthy, the availability of GRE1 could allow the design of novel immunoprophylactic strategies during the immunomodulatory treatment.

AB - JC virus (JCPyV) has gained novel clinical importance as cause of progressive multifocal leukoencephalopathy (PML), a rare demyelinating disease recently associated to immunomodulatory drugs, such as natalizumab used in multiple sclerosis (MS) cases. Little is known about the mechanisms leading to PML, and this makes the need of PML risk stratification among natalizumab-treated patients very compelling. Clinical and laboratory-based risk-stratification markers have been proposed, one of these is represented by the JCPyV-seropositive status, which includes about 54% of MS patients. We recently proposed to investigate the possible protective role of neutralizing humoral immune response in preventing JCPyV reactivation. In this proof-of-concept study, by cloning the first human monoclonal antibody (GRE1) directed against a neutralizing epitope on JCPyV/VP1, we optimized a robust anti-JCPyV neutralization assay. This allowed us to evaluate the neutralizing activity in JCPyV-positive sera from MS patients, demonstrating the lack of correlation between the level of anti-JCPyV antibody and anti-JCPyV neutralizing activity. Relevant consequences may derive from future clinical studies induced by these findings; indeed the study of the serum anti-JCPyV neutralizing activity could allow not only a better risk stratification of the patients during natalizumab treatment, but also a better understanding of the pathophysiological mechanisms leading to PML, highlighting the contribution of peripheral versus central nervous system JCPyV reactivation. Noteworthy, the availability of GRE1 could allow the design of novel immunoprophylactic strategies during the immunomodulatory treatment.

KW - JCPyV

KW - Monoclonal antibody

KW - Multiple sclerosis

KW - Natalizumab

KW - Neutralizing activity

KW - Progressive multifocal leukoencephalopathy (PML)

UR - http://www.scopus.com/inward/record.url?scp=84903170770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903170770&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2014.05.017

DO - 10.1016/j.antiviral.2014.05.017

M3 - Article

C2 - 24909571

AN - SCOPUS:84903170770

VL - 108

SP - 94

EP - 103

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -